$RXII Pharmaceuticals Corporation completes name change to $PHIO Pharmaceuticals Corp. Check out our new website at phiopharma.com and follow us @phio_pharma for updates. prn.to/2PHUIfu
$RXII Reports Q3 2018 #Financial Results & Corporate Highlights:
•Gerrit Dispersyn appointed President & COO
•Planned corporate name change from RXi to Phio
•Extended cash runway
•Reduced net loss
•Announced new #nkcell data using #sdrxrna
prn.to/2PwQF5C
"Pharm Exec's 2019 Pipeline Report" published by @PharmExec includes $RXII development of immuno-oncology therapeutics using its self-delivering RNAi platform: pharmexec.com/pharm-execs-20…
$RXII to present poster at #SITC2018 on 11/10/2018 from 12:20pm – 1:50pm ET & 7:00 – 8:00pm ET. Poster will highlight the potential of #sdrxrna to improve #nkcell potency in #adoptivecelltherapy. prn.to/2QrtwxG
$RXII to webcast third quarter 2018 #Financial results and provide a business update: 11/14/2018 at 4:30pm ET prn.to/2D7tWpi
Cartoons offer a peek into cancer immunotherapy — and scientists’ minds statnews.com/2018/10/17/canc… via @statnews
RXi Pharmaceuticals Announces Closing Of $15 Million Underwritten Public Offering | RXi Pharmaceuticals investors.rxipharma.com/news…
$RXII Announces Pricing of $15M Upsized Underwritten Public Offering ow.ly/kZAU30m2jGm
$RXII presentation today at #BostonDOT18. "The Use of Self-delivering RNAi to Enhance NK Cell Cytotoxicity" - ow.ly/7SpV30lYmiF
#cancer #ImmunoOncology #RNAi #adoptivecelltherapy #Cbl-b
Listen in to RXi's recent webcast presentation to learn about our strategy to tackle different #immune escape mechanisms to treat solid #tumors and view data from our collaborations with #CCIT, #Medigene and #GustaveRoussy #ImmunoOncology ow.ly/XRL930lJc1d
$RXII: Cancer Care’s Next Chapter Could Depend on RNA Interference. "The potential of sd-rxRNA...to address the enduring challenges of undruggable targets...could offer oncologists a new way to address the needs of their patients." #ImmunoOncology #RNAi
ow.ly/QlPh30lJ2M0
$RXII to present at Rodman&Renshaw Global #Investment Conf. 9/5/18 at 3:25 p.m. ET. Update on #ImmunoOncology programs that aim to fill unmet need of other therapeutic approaches and strategy to tackle different #immune escape mechanisms to treat #cancer ow.ly/E6KX30lAdP3
$RXII & #Karolinska Institutet Enter Collaboration to Develop sd-rxRNA Compounds to Improve Functionality and Persistence of #TCells and #NKCells for the Advancement of #ImmunoOncology Therapeutics for #SolidTumors
#cancer #rnai
ow.ly/QvK130lphjL
$RXII Reports Q2 2018 #Financial Results & Corporate Highlights:
•Extended cash runway
•Announced positive #dermatology and #ophthalmology results
•Entered collaboration w/ #Iovance Biotherapeutics
• Strengthened IP estate for sd-rxRNA platform
ow.ly/94Xj30loaW2
$RXII to webcast second quarter 2018 #financial results and provide a business update: 08/14/2018 at 4:30 pm ET. prn.to/2M2awab
$RXII granted patents for sd-rxRNA technology strengthening #IP estate in Europe and Japan. Further provides for multiple #commercial and #development opportunities. #businessdevelopment prn.to/2AAjQxo
$RXII Announces Postive #Results from Phase 1/2 trial with #RXI-109 for #Retinal Scarring #investors #ophthalmology #wetAMD prn.to/2Aul3pR
BioAxone BioSciences Awarded $1.1 Million Phase 2 SBIR Funding for Continued Development of #sd-rxRNA Drug Candidate for the Treatment of Spinal Cord Injury- Collaborator #RXII to receive a portion of the funding prn.to/2IzgJV1
Cancer Immunotherapy and RNA Interference genengnews.com/gen-exclusive… via @genbio
4
RXi leveraging European partnerships to focus on new cancer treatments wbjournal.com/article/201805…
1


